Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 52 Published: March 31, 2022 Report Code: GMDGDHC22005TDB

Vascular Endothelial Growth Factor B also known as VEGFB is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1).

The Vascular Endothelial Growth Factor – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Vascular Endothelial Growth Factor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Vascular Endothelial Growth Factor and features dormant and discontinued projects.

Key Therapy Areas in the Vascular Endothelial Growth Factor B Pipeline Drugs Market

The key therapy areas in the Vascular Endothelial Growth Factor B Pipeline drugs market are Oncology, Ophthalmology, and Metabolic Disorders.

Vascular Endothelial Growth Factor B Pipeline Drugs Market, by Therapy Areas

Vascular Endothelial Growth Factor B Pipeline Drugs Market, by Therapy Areas

For more target insights, download a free report sample

Key MoA in the Vascular Endothelial Growth Factor B Pipeline Drugs Market

The key mechanisms of action in the Vascular Endothelial Growth Factor B Pipeline drugs market are Vascular endothelial growth factor B Inhibitor, Placenta Growth Factor Inhibitor, and Vascular Endothelial Growth Factor A Inhibitor.

Vascular Endothelial Growth Factor B Pipeline Drugs Market, by MoA

Vascular Endothelial Growth Factor B Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Vascular Endothelial Growth Factor B Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Vascular Endothelial Growth Factor B Pipeline drugs market are Subcutaneous, Intravenous, and Intravitreal.

Vascular Endothelial Growth Factor B Pipeline Drugs Market Analysis, by RoA

Vascular Endothelial Growth Factor B Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Vascular Endothelial Growth Factor B Pipeline Drugs Market

The key molecule types in the Vascular Endothelial Growth Factor B Pipeline drugs market are Monoclonal Antibody, and Fusion Protein.

Vascular Endothelial Growth Factor B Pipeline Drugs Market Analysis, by Molecule

Vascular Endothelial Growth Factor B Pipeline Drugs Market Analysis, by Molecule

For more company insights, download a free sample report

Major Companies in the Vascular Endothelial Growth Factor B Pipeline Drugs Market

The major companies in the Vascular Endothelial Growth Factor B Pipeline drugs market are Alvotech ehf, CSL Ltd, GlycoNex Inc, Luye Pharma Group Ltd, Panolos Bioscie, Regeneron Pharmaceuticals Inc, Prestige BioPharma Ltd, Mabwell Shanghai Bioscience Co Ltd and Rophibio Inc among others.

Vascular Endothelial Growth Factor B Pipeline Drugs Market, by Major Companies

Vascular Endothelial Growth Factor B Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Vascular Endothelial Growth Factor B Pipeline Drugs Market Overview

Key Therapy Areas Oncology, Ophthalmology, and Metabolic Disorders
Key Mechanisms of action Vascular Vascular Vascular endothelial growth factor B Inhibitor, Placenta Growth Factor Inhibitor, and Vascular Endothelial Growth Factor A Inhibitor
Key Routes of Administration Subcutaneous, Intravenous, and Intravitreal
Key molecule types Monoclonal Antibody, and Fusion Protein
Major companies Alvotech ehf, CSL Ltd, GlycoNex Inc, Luye Pharma Group Ltd, Panolos Bioscie, Regeneron Pharmaceuticals Inc, Prestige BioPharma Ltd, Mabwell Shanghai Bioscience Co Ltd and Rophibio Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vascular Endothelial Growth Factor
  • The pipeline guide reviews pipeline therapeutics for Vascular endothelial growth factor By companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vascular Endothelial Growth Factor therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Endothelial Growth Factor therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Vascular Endothelial Growth Factor

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vascular Endothelial Growth Factor
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B Pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

  • Alvotech ehf

    CSL Ltd

    GlycoNex Inc

    Luye Pharma Group Ltd

    Mabwell Shanghai Bioscience Co Ltd

    Panolos Bioscience

    Prestige BioPharma Ltd

    Regeneron Pharmaceuticals Inc

    Rophibio Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Overview

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Companies Involved in Therapeutics Development

Alvotech ehf

CSL Ltd

GlycoNex Inc

Luye Pharma Group Ltd

Mabwell Shanghai Bioscience Co Ltd

Panolos Bioscience

Prestige BioPharma Ltd

Regeneron Pharmaceuticals Inc

Rophibio Inc

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Drug Profiles

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

CSL-346 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PB-101 – Drug Profile

Product Description

Mechanism Of Action

ziv-aflibercept – Drug Profile

Product Description

Mechanism Of Action

History of Events

ziv-aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Dormant Products

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Discontinued Products

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Product Development Milestones

Featured News & Press Releases

Feb 10, 2017: Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease

Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL346 in Australia

Mar 24, 2014: NICE rejects life-extending bowel cancer drug two weeks after Scottish approval

Sep 15, 2013: Approved cancer drug potentially could help treat diabetes, researchers find

Jun 20, 2013: NICE Turns Down Sanofi’s Zaltrap For Treatment Of Metastatic Colorectal Cancer

Feb 05, 2013: Sanofi And Regeneron Pharma Receive EU Approval For Zaltrap For Patients With Previously Treated Metastatic Colorectal Cancer

Nov 16, 2012: Sanofi And Regeneron Pharma Announce CHMP Positive Opinion For Zaltrap For Previously Treated Metastatic Colorectal Cancer

Nov 08, 2012: Sanofi Offers Discount On Cancer Drug Zaltrap

Oct 08, 2012: Sanofi Announces Publication Of Phase III Results Of Zaltrap Study In Previously Treated Metastatic Colorectal Cancer Patients In Journal Of Clinical Oncology

Sep 07, 2012: Georgia Health Clinician Studies Zaltrap’s Ability To Prolongs Survival In Patients With Metastatic Colon Cancer

Aug 03, 2012: FDA Approves ZALTRAP After Priority Review For Previously Treated Metastatic Colorectal Cancer

May 16, 2012: Sanofi To Present Data On Zaltrap At American Society Of Clinical Oncology Annual Meeting

Apr 05, 2012: Sanofi And Regeneron Announce ZALTRAP Phase III Study In Prostate Cancer Did Not Meet Primary Endpoint

Apr 05, 2012: Sanofi And Regeneron Receive FDA Priority Review For ZALTRAP Combination Chemotherapy

Sep 23, 2011: Regeneron Announces ZALTRAP Clinical Presentation At EMCC, Sweden

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Alvotech ehf, 2022

Pipeline by CSL Ltd, 2022

Pipeline by GlycoNex Inc, 2022

Pipeline by Luye Pharma Group Ltd, 2022

Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2022

Pipeline by Panolos Bioscience, 2022

Pipeline by Prestige BioPharma Ltd, 2022

Pipeline by Regeneron Pharmaceuticals Inc, 2022

Pipeline by Rophibio Inc, 2022

Dormant Products, 2022

Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.